The National Pharmaceutical Pricing Authority has granted a five-year pricing exemption to Biodeal Pharmaceuticals for its Midazolam nasal spray. This allows the company to set independent market prices for the domestically developed seizure treatment. While the firm recently secured new private funding, it faces ongoing challenges regarding financial transparency and credit ratings.
The National Pharmaceutical Pricing Authority (NPPA) has issued an order granting a five-year price exemption to Biodeal Pharmaceuticals for its Midazolam Nasal Spray (1.25% w/v). This decision, effective retroactively from May 2025, allows the company to bypass standard price-capping mechanisms under the Drugs (Prices Control) Order, 2013. The regulator provided this relief under Para 32(iii), which is designed to incentivize indigenous research and development for novel drug delivery systems.
Strategic Product and Market Context
The Midazolam nasal spray is a specialized formulation intended to treat acute repetitive seizures and provide pre-procedure sedation. Biodeal Pharmaceuticals developed the drug in-house as a non-invasive alternative to traditional injections. By securing this exemption, the company gains the autonomy to price the product independently in the Indian market. While this approval is a significant regulatory milestone for the company’s product pipeline, the exemption applies strictly to this specific nasal spray and not to its broader portfolio of products.
Business and Funding Profile
It is important for investors and market observers to note that Biodeal Pharmaceuticals is a private company and is not listed on the National Stock Exchange (NSE) or the Bombay Stock Exchange (BSE). Despite not being a public entity, the firm is active in the pharmaceutical landscape and has recently adjusted its capital structure. In August 2026, the company raised ₹385 crore from RMB Capitalworks to fund expansion and research initiatives. Additionally, the company successfully redeemed a previous investment from Piramal Alternatives in July 2026, which reportedly yielded a return of over 20%.
Credit Rating and Disclosure Risks
While the company has successfully attracted private capital, it faces transparency challenges. In June 2026, the credit rating agency ICRA downgraded the company’s credit rating to the 'Issuer Not Cooperating' category. This classification generally indicates that the company has not provided sufficient or updated financial information for the agency to conduct an accurate credit assessment. For those monitoring the company’s progress, this lack of financial transparency remains a material risk.
Looking ahead, stakeholders will monitor how Biodeal manages its regulatory obligations. The company is required to maintain transparency by filing mandatory price lists, including the Price to Retailer and Maximum Retail Price, through the prescribed Form V. The long-term commercial success of the product and the company’s ability to resolve its credit rating status through improved financial disclosures will be the primary areas to watch.